Trillium Therapeutics (NASDAQ:TRIL) jumps 40% after hours in response to updated results from early-stage dose-escalation studies of top candidates TTI-621 and TTI-622.
TTI-621 (SIRPa-IgG1 fusion protein): Preliminary data from a four-part Phase 1 open-label trial in patients with relapsed/refractory blood cancers showed that weekly infusions up to 1.4 mg/kg were well-tolerated with no dose-limiting thrombocytopenia (low blood platelets) (response data not yet available). In the 1.0 mg/kg dose arm, there was one complete response and one partial response in six evaluable patients. Two were bridged to allogeneic transplantation. Enrollment in the 2.0 mg/kg cohort is underway.
TTI-622 (SIRPa-IgG4 fusion protein): Preliminary data from a two-part open-label Phase 1 study in patients with relapsed/ refractory lymphoma or multiple myeloma showed a 33% (n=6/18) response rate, five partials and one complete, at the first assessment at week 8. There was one serious dose-limiting toxicity (thrombocytopenia) in the 8 mg/kg cohort (six evaluable patients). Clinical responses were observed across a range of lymphoma types. Enrollment in the 12 mg/kg cohort is underway.
Management hosted a conference call today at 5:30 pm ET to discuss the data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.